A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents

Archives of Internal Medicine

Volumn 163, Issue 6, 2003, Pages 728-734

  Chan, K Arnold ^a,b   Truman, Alison ^c   Gurwitz, Jerry H ^d,e,f   Hurley, Judith S ^g   Martinson, Brian ^h   Platt, Richard ^a,i   Everhart, James E ^j   Moseley, Richard H ^k   Terrault, Norah ^l   Ackerson, Lynn ^c   Selby, Joe V ^c,m  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c KAISER PERMANENTE   (United States)

^d Fallon Healthcare System   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^h HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m DIVISION OF RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INSULIN; METFORMIN; PROTHROMBIN; SULFONYLUREA; TROGLITAZONE;

ACUTE DISEASE; ADULT; AGE; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EXPOSURE; DRUG SAFETY; EVALUATION; FEMALE; GENDER; HEALTH MAINTENANCE ORGANIZATION; HEPATIC ENCEPHALOPATHY; HOSPITAL DISCHARGE; HUMAN; LIVER FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; STANDARD;

ACUTE DISEASE; ADULT; AGED; CHROMANS; COHORT STUDIES; FEMALE; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; LIVER; LIVER FAILURE; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037463895     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.6.728     Document Type: Article

References (33)

1. Kessler DA. Introducing MedWatch, a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765-2768.
2. Faich GA. Adverse-drug-reaction monitoring. N Engl J Med. 1986;314:1589-1592.
3. Wood AJJ, Stein OM, Woosley R. Making medicines safer: the need for an independent drug safety board. N Engl J Med. 1998;339:1851-1854.
4. Ray W, Griffin M, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med. 1993;329:2029-2032.
5. Waller P. Pharmacoepidemiology: a tool for public health. Pharmacoepidemiol Drug Saf. 2001;10:165-172.
6. Spencer CM, Markham A. Troglitazone. Drugs. 1997;54:89-101.
7. Wise J. Diabetes drug withdrawn after reports of hepatic events [news]. BMJ. 1997;315:1564.
8. Henney JE. From the Food and Drug Administration: withdrawal of troglitazone and cisapride. JAMA. 2000;283:2228.
9. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone [letter]. Ann Intern Med. 1998;129:1080.
10. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med. 1998;129:38-41.
11. Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med. 1999;130:163-164.
12. Murphy EJ, Davern TJ, Shakil O, et al. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci. 2000;45:549-553.
13. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916-917.
14. Gale EAM. Lessons from the glitazones: a story of drug development. Lancet. 2001;357:1870-1875.
15. Silverman JF, Pories WJ, Caro JE. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. Pathol Annu. 1989;24:275-302.
16. Everhart JE. Digestive diseases and diabetes. In: Harris MI, Cowie CC, Stearn MP, et al, eds. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health; 1995:469-471. NIH publication 95-1468.
17. Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol. 1997;146:565-571.
18. Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109:588-590.
19. El-Serag HB, Everhart JE. Does diabetes increase the risk of acute hepatic failure [abstract]? Hepatology. 2001;34(suppl):295A.
20. Selby JV. Linking automated databases for research in managed care settings. Ann Intern Med. 1997;127:719-724.
21. Platt R, Davis R, Finkelstein J, et al. Multi-center epidemiologic and health services research on therapeutics in the HMO Research Network. Pharmacoepidemiol Drug Saf. 2001;10:373-378.
22. Clark DO, von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783-795.
23. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wiley & Sons Inc; 1999.
24. Jick S, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care. 1999;22:2067-2071.
25. Lee WM. Medical progress: drug-induced hepatotoxicity. N Engl J Med. 1995;333:1118-1127.
26. Guess HA. How should acute hepatic drug effects be studied epidemiologically? Epidemiology. 1993;4:487-489.
27. Walker AM, Cavanaugh RJ. The occurrence of new hepatic disorders in a defined population. Post Marketing Surveillance. 1992;6:107-117.
28. Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994;154:311-316.
29. Zimmerman HJ. Hepatoxicity. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:753-763.
30. Tawata M, Ikeda M, Kodama Y, Aida K, Onaya T. A type 2 diabetic patient with liver dysfunction due to human insulin. Diabetes Res Clin Pract. 2000;49:17-21.
31. Lumpkin MM. Troglitazone: Presentation to FDA Advisory Committee. May 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3615s1a /sld001.htm. Accessed May 31, 2002.
32. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9:679-685.
33. Kubota K, Kawabe E, Hinotsu S, Hamada C, Ohashi Y, Kurokawa K. Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics. Eur J Clin Pharmacol. 2001;56:831-838.